EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting lysine demethylase 6B ameliorates ASXL1 truncation–mediated myeloid malignancies in preclinical models

Guo Ge, Peng Zhang, Pinpin Sui, Shi Chen, Hui Yang, Ying Guo, Ivan P Rubalcava, Asra Noor, Caroline R Delma, Joel Agosto-Peña, Hui Geng, Edward A Medina und 6 weitere

Journal of Clinical Investigation · 02.01.2024 · 134 (1)

DOI: 10.1172/jci163964 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 02.01.2024. Verfasst von Guo Ge und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Systems and Anatomy. Hauptthemen laut MEDLINE: Histones, Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ASXL1 mutation frequently occurs in all forms of myeloid malignancies and is associated with aggressive disease and poor prognosis. ASXL1 recruits Polycomb repressive complex 2 (PRC2) to specific gene loci to repress transcription through trimethylation of histone H3 on lysine 27 (H3K27me3). ASXL1 alterations reduce H3K27me3 levels, which results in leukemogenic gene expression and the development of myeloid malignancies. Standard therapies for myeloid malignancies have limited efficacy when mutated ASXL1 is present. We discovered upregulation of lysine demethylase 6B (KDM6B), a demethylase for H3K27me3, in ASXL1-mutant leukemic cells, which further reduces H3K27me3 levels and facilitates myeloid transformation. Here, we demonstrated that heterozygous deletion of Kdm6b restored H3K27me3 levels and normalized dysregulated gene expression in Asxl1Y588XTg hematopoietic stem/progenitor cells (HSPCs). Furthermore, heterozygous deletion of Kdm6b decreased the HSPC pool, restored their self-renewal capacity, prevented biased myeloid differentiation, and abrogated progression to myeloid malignancies in Asxl1Y588XTg mice. Importantly, administration of GSK-J4, a KDM6B inhibitor, not only restored H3K27me3 levels but also reduced the disease burden in NSG mice xenografted with human ASXL1-mutant leukemic cells in vivo. This preclinical finding provides compelling evidence that targeting KDM6B may be a therapeutic strategy for myeloid malignancies with ASXL1 mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HistonesNeoplasmsHumansMiceAnimalsLysineRepressor ProteinsTranscription FactorsJumonji Domain-Containing Histone Demethylases

Stichwörter der Autor:innen

HematologyHematopoietic stem cellsLeukemiasMouse models

Substanzen

HistonesLysineRepressor ProteinsTranscription FactorsASXL1 protein, humanKDM6B protein, humanJumonji Domain-Containing Histone Demethylases

Autor:innen und Institutionen

  • Department of Cell Systems and Anatomy.
  • Mays Cancer Center.
  • Department of Molecular Medicine, and.
  • Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
  • Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA.
  • Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.

Förderung

  • NHLBI NIH HHS
  • NIH HHS
  • NCI NIH HHS
  • National Institutes of Health

Zitieren

APA

Ge, G., Zhang, P., Sui, P., Chen, S., Yang, H., Guo, Y., Rubalcava, I. P., Noor, A., Delma, C. R., Agosto-Peña, J., Geng, H., Medina, E. A., Liang, Y., Nimer, S. D., Mesa, R., Abdel-Wahab, O., Xu, M., & Yang, F. C. (2024). Targeting lysine demethylase 6B ameliorates ASXL1 truncation–mediated myeloid malignancies in preclinical models. Journal of Clinical Investigation, 134(1). https://doi.org/10.1172/jci163964

Vancouver

Ge G, Zhang P, Sui P, Chen S, Yang H, Guo Y, et al. Targeting lysine demethylase 6B ameliorates ASXL1 truncation–mediated myeloid malignancies in preclinical models. Journal of Clinical Investigation. 2024;134(1). doi:10.1172/jci163964

BibTeX
@article{Ge2024,
  author = {Ge, Guo and Zhang, Peng and Sui, Pinpin and Chen, Shi and Yang, Hui and Guo, Ying and Rubalcava, Ivan P and Noor, Asra and Delma, Caroline R and Agosto-Peña, Joel and Geng, Hui and Medina, Edward A and Liang, Ying and Nimer, Stephen D and Mesa, Ruben and Abdel-Wahab, Omar and Xu, Mingjiang and Yang, Feng-Chun},
  title = {Targeting lysine demethylase 6B ameliorates ASXL1 truncation–mediated myeloid malignancies in preclinical models},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  volume = {134},
  number = {1},
  doi = {10.1172/jci163964}
}
Kostenlos starten →